Patterns of use of oral adjuvant endocrine therapy in Australian breast cancer survivors 5 years from diagnosis

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Most women with HR+ breast cancer who survive at least 5 years have persisted with OAET despite the adverse effects of estrogen depletion.
Original languageEnglish
Pages (from-to)721 - 726
Number of pages6
JournalMenopause
Volume20
Issue number7
DOIs
Publication statusPublished - 2013

Cite this

@article{bf2744e993ac4892bcb7b526dc7d9195,
title = "Patterns of use of oral adjuvant endocrine therapy in Australian breast cancer survivors 5 years from diagnosis",
abstract = "Most women with HR+ breast cancer who survive at least 5 years have persisted with OAET despite the adverse effects of estrogen depletion.",
author = "Bell, {Robin Jean} and Schwarz, {Max Allan} and Pam Fradkin and Robinson, {Penelope Jane} and Davis, {Susan Ruth}",
year = "2013",
doi = "10.1097/GME.0b013e31827ce094",
language = "English",
volume = "20",
pages = "721 -- 726",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams & Wilkins",
number = "7",

}

TY - JOUR

T1 - Patterns of use of oral adjuvant endocrine therapy in Australian breast cancer survivors 5 years from diagnosis

AU - Bell, Robin Jean

AU - Schwarz, Max Allan

AU - Fradkin, Pam

AU - Robinson, Penelope Jane

AU - Davis, Susan Ruth

PY - 2013

Y1 - 2013

N2 - Most women with HR+ breast cancer who survive at least 5 years have persisted with OAET despite the adverse effects of estrogen depletion.

AB - Most women with HR+ breast cancer who survive at least 5 years have persisted with OAET despite the adverse effects of estrogen depletion.

UR - http://www.ncbi.nlm.nih.gov/pubmed/23793165

U2 - 10.1097/GME.0b013e31827ce094

DO - 10.1097/GME.0b013e31827ce094

M3 - Article

VL - 20

SP - 721

EP - 726

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 7

ER -